{"protocolSection":{"identificationModule":{"nctId":"NCT04629872","orgStudyIdInfo":{"id":"MRCTA, ECFAH of FMU [2020]296"},"organization":{"fullName":"First Affiliated Hospital of Fujian Medical University","class":"OTHER"},"briefTitle":"Fingolimod in Endovascular Treatment of Ischemic Stroke","officialTitle":"Combinating Fingolimod With Endovascular Treatment in Acute Ischemic Stroke"},"statusModule":{"statusVerifiedDate":"2022-04","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-11-12","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-12-30","type":"ESTIMATED"},"completionDateStruct":{"date":"2023-12-30","type":"ESTIMATED"},"studyFirstSubmitDate":"2020-11-11","studyFirstSubmitQcDate":"2020-11-13","studyFirstPostDateStruct":{"date":"2020-11-16","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-04-12","lastUpdatePostDateStruct":{"date":"2022-04-13","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR_INVESTIGATOR","investigatorFullName":"Ning Wang, MD., PhD.","investigatorTitle":"Director of Neurology department","investigatorAffiliation":"First Affiliated Hospital of Fujian Medical University"},"leadSponsor":{"name":"Ning Wang, MD., PhD.","class":"OTHER"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Proof-of concept clinical trials have indicated that the sphingosine-1-phosphate receptor modulator fingolimod may be efficacious in attenuating brain inflammation and improving clinical outcomes in patients with acute ischemic stroke as a single therapy beyond 4.5 hours of disease onset, or in combination with alteplase within 4.5 hours of disease onset. This study aim to determine whether fingolimod enhance the action of endovascular treatment for acute ischemic stroke"},"conditionsModule":{"conditions":["Stroke Inflammation"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":30,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"endovascular treatment with fingolimod","type":"EXPERIMENTAL","interventionNames":["Drug: Fingolimod"]},{"label":"endovascular treatment without fingolimod","type":"NO_INTERVENTION"}],"interventions":[{"type":"DRUG","name":"Fingolimod","description":"Patients randomized to fingolimod will also receive oral fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is more than 3 hour prior to mechanical thrombectomy.","armGroupLabels":["endovascular treatment with fingolimod"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"the grade of collateral circulation","description":"Multiphasic contrast-enhanced CT collateral grades with six-point pial arterial filling ordinary score as established at the University of Calgary","timeFrame":"Baseline (before endovascular treatment)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients presenting with anterior circulation acute ischaemic stroke who are eligible for mechanical thrombectomy commenced within 6-24 hours of stroke onset.\n* Patient, family member or legally responsible person depending on local ethics requirements has given informed consent.\n* Patient's age is 18-80 years.\n* Arterial occlusion on internal carotid artery proximal or middle cerebral artery\n* Imaging inclusion criteria: infarct core volume between 15-70 mL\n\nExclusion Criteria:\n\n* Pre-existing neurologic disability (a score greater than 2 on the mRS).\n* Swallowing difficulties that would prevent administration of oral fingolimod.\n* Patients with any history of bradyarrhythmia, atrioventricular block or current use of beta-blockers or verapamil.\n* Patients with serious acute or chronic infection, or hepatic injury\n* Concomitant use of antineoplastic, immunosuppressive or immune modulating therapies.\n* Macular edema.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"fu ying, MD","role":"CONTACT","phone":"13920263588","email":"fuying1995@163.com"}],"locations":[{"facility":"The First Affiliated Hospital of Fujian Medical University","status":"RECRUITING","city":"Fuzhou","zip":"350000","country":"China","contacts":[{"name":"Ying Fu","role":"CONTACT","phone":"+8613920263688","email":"fuying@fjmu.eu.cn"}],"geoPoint":{"lat":26.06139,"lon":119.30611}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000007249","term":"Inflammation"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9983","name":"Inflammation","asFound":"Inflammation","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068876","term":"Fingolimod Hydrochloride"}],"ancestors":[{"id":"D000081243","term":"Sphingosine 1 Phosphate Receptor Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000007166","term":"Immunosuppressive Agents"},{"id":"D000007155","term":"Immunologic Factors"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M323","name":"Fingolimod Hydrochloride","asFound":"Radiation treatment","relevance":"HIGH"},{"id":"M239032","name":"Lactitol","relevance":"LOW"},{"id":"M9902","name":"Immunosuppressive Agents","relevance":"LOW"},{"id":"M9891","name":"Immunologic Factors","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Gast","name":"Gastrointestinal Agents"}]}},"hasResults":false}